Superworth

TriSalus Life Sciences profit margin TLSI

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
−62.6%
Operating margin, 12 months
−67.7%
Net margin on a year earlier
+24.0 pts
Peer median
6.9%

Over the twelve months to Jun 30, 2026, TriSalus Life Sciences kept −62.6% of its revenue as net profit, with an operating margin of −67.7% and a gross margin of 85.8%.

The median for 10 medical instruments and supplies stocks of a similar size is 6.9%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025−86.9%−59.7%84.6%
FY2024n/an/a86.1%
FY2023n/an/a85.9%
FY2022n/an/an/a
FY2021n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26−62.6%+24.0 pts−67.7%
Q1 FY26−60.9%+23.8 pts−62.4%
Q4 FY25−86.9%n/a−59.7%
Q3 FY25−98.4%n/a−77.7%
Q2 FY25−86.6%n/a−86.1%
Q1 FY25−84.7%n/a−99.0%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Medical - Instruments & Supplies nearest TriSalus Life Sciences' size, closest first, today.

CompanyProfit margin
TLSITriSalus Life Sciences−62.6%
UTMDUtah Medical Products29.0%
PDEXPro DEX17.6%
INFUInfuSystem6.0%
EMBCEmbecta8.6%
KEQUKewaunee Scientific3.0%
TCMDTactile Systems Technology7.1%
MDXGMimedx1.8%
MOVMovado6.0%
APTAlpha Pro Tech6.8%
IRMDIradimed26.7%
Peer median6.9%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on TriSalus Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.